Pharmaceutical Technology: ESC 2024: Obesity Drugs Emerge as Attractive Tool for Heart Failure Prevention

Cardiology experts discussed the relationship between obesity and heart failure while referencing new clinical trial results at the European Society of Cardiology (ESC) 2024 Congress.

In one presentation, Dr. Mikhail Kosiborod, cardiologist and vice president of research at Saint Luke’s Mid America Heart Institute, emphasized the importance of understanding the systemic and local effects of obesity on heart failure and the need for further studies to comprehend the relationship between visceral adiposity and heart failure. Specifically, Kosiborod focused on different treatment strategies, such as lifestyle interventions, bariatric surgery and medications for the prevention of obesity to reduce the risk of heart failure and relevant clinical trial results.

Read the full Pharmaceutical Technology article: ESC 2024: Obesity Drugs Emerge as Attractive Tool for Heart Failure Prevention

Related Content

Aug. 31, 2024

American Journal of Managed Care: Semaglutide Enhances Heart Failure Outcomes in Obesity
A new subanalysis presented by Dr. Mikhail Kosiborod shows benefits of semaglutide in patients with aFib.
Apr. 8, 2024

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Obesity-Related Heart Failure and Type 2 Diabetes
A new study led by Dr. Mikhail Kosiborod found patients with obesity-related heart failure and type 2 diabetes had significant improvement in symptoms and physical limitations when taking semaglutide.
Aug. 25, 2023

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Heart Failure
STEP-HFpEF trial findings were presented during the opening late breaking clinical trial session at the European Society of Cardiology Congress in Amsterdam, Netherlands.